Do Systemic Alpha-2 Agonists Lower Glaucoma Risk? - Top-Institutions - MDSpire

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.

  • By

  • Andrea Surnit

  • July 8, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    University of California, Riverside School of Medicine
    University of California, Riverside School of Medicine

    Riverside, California

    Key Differentiators

    • Ophthalmology

  • #2

    Hamilton Glaucoma Center, University of California at San Diego
    Hamilton Glaucoma Center, University of California at San Diego

    La Jolla, California

    Key Differentiators

    • Ophthalmology

  • #3

    Glaucoma Institute of State College
    Glaucoma Institute of State College

    State College, Pennsylvania

    Key Differentiators

    • Ophthalmology

  • #4

    Nittany Eye Associates
    Nittany Eye Associates

    State College, Pennsylvania

    Key Differentiators

    • Ophthalmology

  • #5

    Clayton Eye Center
    Clayton Eye Center

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

Original Source(s)

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

  • by Andrea Surnit

  • July 8, 2026

Related Content

Phacoemulsification with goniosynechialysis for nanophthalmos with secondary angle-closure or secondary angle-closure glaucoma: a 20-case series and stepwise management strategy

FDA Clears Nocturnal IOP Device

Balance Ophthalmics gains FDA 510(k) clearance for wireless FSYX glaucoma device

  • May 26, 2026

  • 2 min
The retinal nerve fibre layer thickness slope: a localised biomarker of the structure–function relationship in early glaucoma